Novantrone® (mitoxantrone for injection concentrate)
Novantrone is an anthracenedione used as an intravenous chemotherapy agent. Novantrone in combination with other approved drugs is approved by the FDA for the treatment of acute non-lymphocytic leukemia (ANLL) in adults, which includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. Novantrone in combination with corticosteroids is also indicated for the treatment of pain associated with advanced hormone-refractory prostate cancer (HRPC). OSI markets and promotes Novantrone for the approved oncology indications in the U.S. pursuant to a co-promotion agreement with an affiliate of Merck Serono, S.A. signed in March 2003.
Novantrone is also approved for certain advanced forms of multiple sclerosis (MS), marketed by Serono, Inc.
For more information, please refer to the Novantrone® Prescribing Information.
For more information on Novantrone®, call 1-800-572-1932.